ZabBio, Inc.

San Diego, CA · Biotech · Private

Monoclonal antibody cocktail therapeutic against ricin toxin exposure

zabbio.com →
Grants
$2.6M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Post-exposure immunotherapy for ricin exposure$1,585,211
Federal grantDepartment of Health and Human Services · Phase II · Post-exposure immunotherapy for ricin exposure$788,841
Federal grantDepartment of Health and Human Services · Phase II · Development of a monoclonal therapy for neonatal herpes$248,531
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1695Epigen Biosciences, Inc.——
1696ONECYTE BIOTECHNOLOGIES, INC.——
1697Igenica——
1698ZabBio, Inc.——
1699EVOQ THERAPEUTICS, INC.——
1700OMass Therapeutics——
1701Purespring Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Mrna-encoded Antibodies For Contraceptionapplication
  • Mrna-encoded Antibodies For Contraceptionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.